Clicky

Akari Therapeutics Plc(AKTX)

Description: Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. The company develops Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b – 9 (membrane attack complex or MAC). It develops products to treat rare diseases, such as paroxysmal nocturnal haemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), myasthenia gravis (MG), Guillain Barré syndrome (GBS), and Sjögren's syndrome. The company was formerly known as Volution Immuno Pharmaceuticals SA and changed its name to Akari Therapeutics, Plc in September 2015. The company is based in New York, New York. Akari Therapeutics, Plc operates as a subsidiary of RPC Pharma Limited.


Keywords: Medicine Biopharmaceutical Organ Systems Rare Diseases Inflammatory Diseases Autoimmunity Myasthenia Gravis Autoimmune And Inflammatory Disease Complement System Paroxysmal Nocturnal Hemoglobinuria Myasthenia Sjögren's Syndrome Acquired Hemolytic Anemia Guillain Barré Syndrome Hemoglobinuria Hemolytic Uremic Syndrome C5a

Home Page: www.akaritx.com

AKTX Technical Analysis

75/76 Wimpole Street
London, W1G 9RT
United Kingdom
Phone: 44 20 8004 0270


Officers

Name Title
Dr. Ray Prudo-Chlebosz M.D. Exec. Chairman
Dr. Torsten Hombeck Chief Financial Officer
Ms. Rachelle Suzanne Jacques Pres, CEO & Director
Ms. Melissa Bradford-Klug Chief Operating Officer
Dr. Miles Nunn Chief Scientific Officer
Dr. John F. Neylan III, M.D. Exec. VP & Chief Medical Officer
Annie Mack Financial Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 3.4316
Price-to-Sales TTM: 0
IPO Date: 2015-09-21
Fiscal Year End: December
Full Time Employees: 9
Back to stocks